Gyre Therapeutics Finalizes $300M Cullgen Acquisition, Appoints New CEO/CFO, and Seeks Shareholder Vote on Preferred Stock Conversion

summarizeSummary

Gyre Therapeutics has finalized its $300 million all-stock acquisition of Cullgen Inc., appointed new executive leadership including a new CEO and CFO, and is seeking shareholder approval for the conversion of Series B Preferred Stock issued in the merger.

check_boxKey Events

• Cullgen Acquisition Finalized

  Gyre Therapeutics completed its $300 million all-stock acquisition of Cullgen Inc., establishing a U.S.- and China-based biopharmaceutical company. This follows the 8-K filing on May 4, 2026, announcing the completion.

• New Executive Leadership Appointed

  Dr. Ying Luo, former CEO of Cullgen, was appointed President and CEO of Gyre. Thomas Eastling was appointed CFO, succeeding Ruoyu Chen. Ping Zhang remains Chairman of the Board.

• Board Changes

  Thomas Eastling and Songjiang Ma resigned from the board of directors, with Dr. Luo joining as a Class I director.

• Shareholder Vote on Preferred Stock Conversion

  Gyre issued Series B Convertible Preferred Stock as merger consideration. Shareholder approval is required at the June 10, 2026 Annual Meeting for the conversion of this preferred stock into common stock.

auto_awesomeAnalysis

Gyre Therapeutics has completed its previously announced $300 million all-stock acquisition of Cullgen Inc., a strategic move that significantly expands its pipeline and establishes it as a U.S.- and China-based fully integrated biopharmaceutical company. This acquisition, valued at approximately 40% of Gyre's market capitalization, is a major corporate event. As part of the integration, Dr. Ying Luo, former CEO of Cullgen, has been appointed President and CEO of Gyre, and Thomas Eastling has been named CFO. The company also issued Series B Convertible Preferred Stock as part of the merger consideration, which requires shareholder approval for its conversion into common stock at the upcoming Annual Meeting on June 10, 2026. This vote is critical for the full financial and governance integration of the combined entity. The transaction is accounted for as a combination of entities under common control, leading to retrospective adjustments in financial statements.